1887

Abstract

Febrile neutropenic patients are at a high risk of life-threatening bacterial infections. Tigecycline was developed to treat multidrug-resistant isolates, however resistance to tigecycline in Klebsiella pneumoniae has been reported. Here, we investigated tigecycline resistance among K. pneumoniae isolated from febrile neutropenic patients admitted to Hematology ICU, Egypt. Out of 75 enrolled febrile neutropenic patients, 48 cases showed bacteriologically confirmed infection. The majority of cases were infected with K. pneumoniae, of which nine were tigecycline non-susceptible. Expression levels of the efflux pump genes acrB and oqxB and their regulatory genes ramA and rarA were analysed. Six isolates had overexpression of the four efflux-related genes while one showed baseline expression. This study emphasizes the importance of growing tigecycline resistance in K. pneumoniae infecting febrile neutropenic patients. Concerning the mechanism of resistance, it was clear that the ramA gene plays the major role, although alternative resistance mechanisms may also exist.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000770
2018-05-25
2019-10-23
Loading full text...

Full text loading...

/deliver/fulltext/jmm/67/7/972.html?itemId=/content/journal/jmm/10.1099/jmm.0.000770&mimeType=html&fmt=ahah

References

  1. Lakshmaiah KC, Malabagi AS, Govindbabu, Shetty R, Sinha M et al. Febrile neutropenia in hematological malignancies: clinical and microbiological profile and outcome in high risk patients. J Lab Physicians 2015;7:116–120 [CrossRef][PubMed]
    [Google Scholar]
  2. Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis 2005;40:S240–S245 [CrossRef][PubMed]
    [Google Scholar]
  3. Antoniadou A, Giamarellou H. Fever of unknown origin in febrile leukopenia. Infect Dis Clin North Am 2007;21:1055–1090 [CrossRef][PubMed]
    [Google Scholar]
  4. Lima SS, França MS, Godoi CC, Martinho GH, de Jesus LA et al. Neutropenic patients and their infectious complications at a University Hospital. Rev Bras Hematol Hemoter 2013;35:18–22 [CrossRef][PubMed]
    [Google Scholar]
  5. Hawkey P, Finch R. Tigecycline: in-vitro performance as a predictor of clinical efficacy. Clin Microbiol Infect 2007;13:354–362 [CrossRef][PubMed]
    [Google Scholar]
  6. Slover CM, Rodvold KA, Danziger LH. Tigecycline: a novel broad-spectrum antimicrobial. Ann Pharmacother 2007;41:965–972 [CrossRef][PubMed]
    [Google Scholar]
  7. Zhong X, Xu H, Chen D, Zhou H, Hu X et al. First emergence of acrAB and oqxAB mediated tigecycline resistance in clinical isolates of Klebsiella pneumoniae pre-dating the use of tigecycline in a Chinese hospital. PLoS One 2014;9:e115185 [CrossRef][PubMed]
    [Google Scholar]
  8. Sun Y, Cai Y, Liu X, Bai N, Liang B et al. The emergence of clinical resistance to tigecycline. Int J Antimicrob Agents 2013;41:110–116 [CrossRef][PubMed]
    [Google Scholar]
  9. Hornsey M, Ellington MJ, Doumith M, Scott G, Livermore DM et al. Emergence of AcrAB-mediated tigecycline resistance in a clinical isolate of Enterobacter cloacae during ciprofloxacin treatment. Int J Antimicrob Agents 2010;35:478–481 [CrossRef][PubMed]
    [Google Scholar]
  10. Chiu SK, Chan MC, Huang LY, Lin YT, Lin JC et al. Tigecycline resistance among carbapenem-resistant Klebsiella pneumoniae: clinical characteristics and expression levels of efflux pump genes. PLoS One 2017;12:e0175140 [CrossRef][PubMed]
    [Google Scholar]
  11. Ruzin A, Immermann FW, Bradford PA. Real-time PCR and statistical analyses of acrAB and ramA expression in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 2008;52:3430–3432 [CrossRef][PubMed]
    [Google Scholar]
  12. Hentschke M, Wolters M, Sobottka I, Rohde H, Aepfelbacher M. ramR mutations in clinical isolates of Klebsiella pneumoniae with reduced susceptibility to tigecycline. Antimicrob Agents Chemother 2010;54:2720–2723 [CrossRef][PubMed]
    [Google Scholar]
  13. Deng M, Zhu MH, Li JJ, Bi S, Sheng ZK et al. Molecular epidemiology and mechanisms of tigecycline resistance in clinical isolates of Acinetobacter baumannii from a Chinese university hospital. Antimicrob Agents Chemother 2014;58:297–303 [CrossRef][PubMed]
    [Google Scholar]
  14. Li R, Han Y, Zhou Y, Du Z, Wu H et al. Tigecycline susceptibility and molecular resistance mechanisms among clinical Klebsiella pneumoniae strains isolated during non-tigecycline treatment. Microb Drug Resist 2017;23:139–146 [CrossRef][PubMed]
    [Google Scholar]
  15. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038–3051 [CrossRef][PubMed]
    [Google Scholar]
  16. CLSI M100-S25 Performance Standards for Antimicrobial Susceptibility Testing. Twenty-Fifth Informational Supplement 2015
    [Google Scholar]
  17. Nigo M, Cevallos CS, Woods K, Flores VM, Francis G et al. Nested case-control study of the emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2013;57:5743–5746 [CrossRef][PubMed]
    [Google Scholar]
  18. van Duin D, Cober ED, Richter SS, Perez F, Cline M et al. Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance. Clin Microbiol Infect 2014;20:O1117–O1120 [CrossRef][PubMed]
    [Google Scholar]
  19. Roy S, Datta S, Viswanathan R, Singh AK, Basu S. Tigecycline susceptibility in Klebsiella pneumoniae and Escherichia coli causing neonatal septicaemia (2007–10) and role of an efflux pump in tigecycline non-susceptibility. J Antimicrob Chemother 2013;68:1036–1042 [CrossRef][PubMed]
    [Google Scholar]
  20. Juan CH, Huang YW, Lin YT, Yang TC, Wang FD. Risk factors, outcomes, and mechanisms of tigecycline-nonsusceptible Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother 2016;60:7357–7363 [CrossRef][PubMed]
    [Google Scholar]
  21. Bialek-Davenet S, Lavigne JP, Guyot K, Mayer N, Tournebize R et al. Differential contribution of AcrAB and OqxAB efflux pumps to multidrug resistance and virulence in Klebsiella pneumoniae. J Antimicrob Chemother 2015;70:81–88 [CrossRef][PubMed]
    [Google Scholar]
  22. Veleba M, Higgins PG, Gonzalez G, Seifert H, Schneiders T. Characterization of RarA, a novel AraC family multidrug resistance regulator in Klebsiella pneumoniae. Antimicrob Agents Chemother 2012;56:4450–4458 [CrossRef][PubMed]
    [Google Scholar]
  23. Sheng ZK, Hu F, Wang W, Guo Q, Chen Z et al. Mechanisms of tigecycline resistance among Klebsiella pneumoniae clinical isolates. Antimicrob Agents Chemother 2014;58:6982–6985 [CrossRef][PubMed]
    [Google Scholar]
  24. Wang X, Chen H, Zhang Y, Wang Q, Zhao C et al. Genetic characterisation of clinical Klebsiella pneumoniae isolates with reduced susceptibility to tigecycline: Role of the global regulator RamA and its local repressor RamR. Int J Antimicrob Agents 2015;45:635–640 [CrossRef][PubMed]
    [Google Scholar]
  25. Veleba M, Schneiders T. Tigecycline resistance can occur independently of the ramA gene in Klebsiella pneumoniae. Antimicrob Agents Chemother 2012;56:4466–4467 [CrossRef][PubMed]
    [Google Scholar]
  26. Veleba M, de Majumdar S, Hornsey M, Woodford N, Schneiders T. Genetic characterization of tigecycline resistance in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes. J Antimicrob Chemother 2013;68:1011–1018 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000770
Loading
/content/journal/jmm/10.1099/jmm.0.000770
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error